Xelpros

Indicated For

glaucoma, ocular hypertension

About This Medication

# XELPROS Xpress Patient Guide: How to Get Xelpros at Low or No Cost XELPROS Xpress is Sun Pharma's access program that allows patients with a prescription for **Xelpros (latanoprost ophthalmic emulsion) 0.005%** to obtain this medication at a fixed low price of $55 for a 1-month supply or $37 per month for a 3-month supply, available directly through participating pharmacies without prior authorization, step therapy, copays, or coupons[1][7]. This patient-friendly guide explains everything you need to know about the program, from eligibility to application steps, helping you access this important glaucoma treatment affordably. ## About Xelpros: What It Treats and Why It's Special **Xelpros** is the only FDA-approved benzalkonium chloride-free (BAK-free) formulation of latanoprost, a prostaglandin analog used to lower intraocular pressure (IOP) in patients with **open-angle glaucoma** or **ocular hypertension**[1][8]. BAK is a common preservative in eye drops that can irritate sensitive eyes over time; Xelpros eliminates this issue while delivering the same effective IOP reduction—typically 6-8 mmHg in clinical trials[8]. The recommended dose is **one drop in the affected eye(s) once daily in the evening**. Effects start within 3-4 hours, peaking at 8-12 hours. Common side effects include eye pain/stinging (55% of patients) and redness (41%), but less than 1% stopped treatment due to intolerance[1]. Avoid using with thimerosal-containing drugs (wait 5 minutes between drops), and consult your doctor if you have active eye inflammation or macular edema risk factors[1][8]. Always follow your eye care professional's advice and read the full prescribing information. Xelpros was FDA-approved in 2018 and launched by Sun Pharma's ophthalmic division to provide a gentler alternative for long-term eye drop users[1][8]. ## Who Qualifies for XELPROS Xpress? This program is designed for **anyone with a valid prescription for Xelpros**—no strict income limits, insurance checks, or financial hardship proof required[1][7]. It's open to all U.S. patients facing high out-of-pocket costs, making it simpler than traditional patient assistance programs (PAPs) that often demand extensive eligibility criteria[4]. Key benefits: - Fixed pricing: $55/month or $37/month (3-month supply saves $41 overall)[1][7]. - No prior authorization or step therapy hassles. - Available nationwide through pharmacies in the XELPROS Xpress network. - Refill reminders and prompt fulfillment support[1]. If you're uninsured, underinsured, or just tired of variable copays, this program guarantees consistent low costs. ## Income Eligibility Breakdown Unlike many PAPs with federal poverty level (FPL) thresholds (e.g., 400-500% FPL), **XELPROS Xpress has no income eligibility**—it's a flat-rate access program for all prescribed patients[1]. This removes barriers like proving household size or income, which can delay care in glaucoma where consistent treatment prevents vision loss. For context, here's how traditional PAPs compare (general examples, not Xelpros-specific): | Household Size | Typical PAP Income Limit (400% FPL) | XELPROS Xpress | |---------------|-------------------------------------|---------------| | Individual | ~$60,000/year | No limit | | Couple | ~$81,000/year | No limit | | Family of 3 | ~$102,000/year | No limit | | Family of 4 | ~$123,000/year | No limit | XELPROS Xpress prioritizes ease over income verification, ensuring quick access[1][4]. ## Insurance Requirements **No insurance restrictions**—the program works for commercially insured, Medicare, Medicaid, or uninsured patients[1][7]. It bypasses copay accumulators and provides direct pharmacy pricing, avoiding pharmacy benefit manager (PBM) games that inflate costs. Medicare Part D users can use this as a cash-pay option if copays exceed $55/month. Check Xelpros.com or call for pharmacy network details[1]. ## Step-by-Step Application Process Getting started is straightforward—no forms or applications needed beyond your prescription[1]. 1. **Get Prescribed**: Ask your eye doctor for Xelpros if it's right for your glaucoma or ocular hypertension. 2. **Contact the Program**: Call **1-800-818-4555** (Sun Pharma support) or visit **Xelpros.com** for more info and pharmacy locator[1][4]. 3. **Find a Participating Pharmacy**: Use the program's network for nationwide distribution. 4. **Fill Prescription**: Present your Rx at the pharmacy—pay the fixed $55 (1-month) or $111 (3-month, or $37/month equivalent). 5. **Receive and Refill**: Enjoy prompt delivery, reminders, and high-quality service[1]. No documents required upfront, making it faster than PAPs needing tax returns or pay stubs[4]. ## Timeline and Delivery Fulfillment is **prompt**—often same-day or next-day at pharmacies, with reliable shipping if needed[1]. Refills come with automated reminders to maintain adherence, critical for glaucoma control. Expect your first supply within days of calling[1]. ## Alternatives if Denied or Ineligible Denials are rare since there's no formal application, but if a pharmacy isn't participating: - Use discount services like GoodRx, BlinkHealth, or Rx Outreach[4][6]. - Explore general PAPs via Partnership for Prescription Assistance (1-888-477-2669) or NeedyMeds (1-800-503-6897)[4][6]. - Generic latanoprost (with BAK) or other glaucoma drops like Zioptan® (1-800-727-5400)[4]. - Pan Foundation grants (1-866-316-7263)[4]. No biosimilars listed for Xelpros[provided data]. Sun Pharma doesn't list a free PAP for Xelpros, but check RxAssist.org for updates[3][6]. ## Important Disclaimer This guide is for informational purposes only and based on publicly available data as of program launch[1][4]. Program details like pricing or availability may change—always verify with Sun Pharma at 1-800-818-4555 or Xelpros.com. Not medical advice; consult your healthcare provider before starting Xelpros. Sun Pharma and affiliates disclaim liability for use of this information. Adherence to prescribed therapy is key to managing glaucoma[1][8]. (Word count: 1028)

Program information last verified: March 29, 2026